SK168196A3 - Anti-hiv triple combination - Google Patents
Anti-hiv triple combination Download PDFInfo
- Publication number
- SK168196A3 SK168196A3 SK1681-96A SK168196A SK168196A3 SK 168196 A3 SK168196 A3 SK 168196A3 SK 168196 A SK168196 A SK 168196A SK 168196 A3 SK168196 A3 SK 168196A3
- Authority
- SK
- Slovakia
- Prior art keywords
- hiv
- combination
- zidovudine
- lamivudine
- loviride
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP94201897 | 1994-07-01 | ||
| PCT/EP1995/002462 WO1996001110A2 (en) | 1994-07-01 | 1995-06-23 | Anti-hiv triple combination |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SK168196A3 true SK168196A3 (en) | 1997-05-07 |
Family
ID=8217000
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1681-96A SK168196A3 (en) | 1994-07-01 | 1995-06-23 | Anti-hiv triple combination |
Country Status (25)
| Country | Link |
|---|---|
| EP (1) | EP0768881B1 (et) |
| JP (1) | JP2945481B2 (et) |
| KR (1) | KR100218495B1 (et) |
| CN (1) | CN1091599C (et) |
| AP (1) | AP9600896A0 (et) |
| AT (1) | ATE218867T1 (et) |
| AU (1) | AU693911B2 (et) |
| BG (1) | BG101175A (et) |
| BR (1) | BR9508201A (et) |
| CA (1) | CA2193489A1 (et) |
| CZ (1) | CZ375596A3 (et) |
| DE (1) | DE69527066T2 (et) |
| EE (1) | EE9600180A (et) |
| FI (1) | FI965292A0 (et) |
| HU (1) | HUT77720A (et) |
| IL (1) | IL114415A0 (et) |
| MX (1) | MX9700044A (et) |
| MY (1) | MY130597A (et) |
| NO (1) | NO965556L (et) |
| OA (1) | OA10341A (et) |
| PL (1) | PL317891A1 (et) |
| SK (1) | SK168196A3 (et) |
| TW (1) | TW401303B (et) |
| WO (1) | WO1996001110A2 (et) |
| ZA (1) | ZA955471B (et) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998008539A1 (en) * | 1996-08-26 | 1998-03-05 | Chiron Corporation | Postinfection human immunodeficiency virus (hiv) vaccination therapy |
| EP0872233A1 (en) * | 1997-04-14 | 1998-10-21 | Janssen Pharmaceutica N.V. | Antiretroviral compositions with improved bioavailability |
| JP4919566B2 (ja) | 1999-09-24 | 2012-04-18 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 抗ウイルス組成物 |
| MY169670A (en) * | 2003-09-03 | 2019-05-08 | Tibotec Pharm Ltd | Combinations of a pyrimidine containing nnrti with rt inhibitors |
| US9044509B2 (en) | 2006-02-03 | 2015-06-02 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Inhibition of HIV infection through chemoprophylaxis |
| AR065720A1 (es) | 2007-03-14 | 2009-06-24 | Tibotec Pharm Ltd | Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso. |
| EP2435052B1 (en) | 2009-05-27 | 2015-07-15 | Hetero Research Foundation | Solid oral dosage forms of lamivudine with isomalt |
| WO2018119371A1 (en) * | 2016-12-23 | 2018-06-28 | Temple University - Of The Commonwealth System Of Higher Education | Anti-flaviviridae activity of anti-retroviral non-nucleoside (nnrtis) and nucleoside reverse transcriptase inhibitors (nnrtis) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK0513917T4 (da) * | 1991-05-16 | 2001-06-25 | Glaxo Group Ltd | Antivirale kombinationer indeholdende nukleosidanaloger |
-
1994
- 1994-05-25 TW TW084105260A patent/TW401303B/zh active
-
1995
- 1995-06-23 WO PCT/EP1995/002462 patent/WO1996001110A2/en active IP Right Grant
- 1995-06-23 EP EP95924930A patent/EP0768881B1/en not_active Expired - Lifetime
- 1995-06-23 EE EE9600180A patent/EE9600180A/et unknown
- 1995-06-23 BR BR9508201A patent/BR9508201A/pt not_active Application Discontinuation
- 1995-06-23 AU AU29248/95A patent/AU693911B2/en not_active Ceased
- 1995-06-23 PL PL95317891A patent/PL317891A1/xx unknown
- 1995-06-23 DE DE69527066T patent/DE69527066T2/de not_active Expired - Fee Related
- 1995-06-23 CN CN95193943A patent/CN1091599C/zh not_active Expired - Fee Related
- 1995-06-23 SK SK1681-96A patent/SK168196A3/sk unknown
- 1995-06-23 JP JP8503654A patent/JP2945481B2/ja not_active Expired - Fee Related
- 1995-06-23 CZ CZ963755A patent/CZ375596A3/cs unknown
- 1995-06-23 MX MX9700044A patent/MX9700044A/es unknown
- 1995-06-23 CA CA002193489A patent/CA2193489A1/en not_active Abandoned
- 1995-06-23 AP APAP/P/1996/000896A patent/AP9600896A0/en unknown
- 1995-06-23 AT AT95924930T patent/ATE218867T1/de not_active IP Right Cessation
- 1995-06-23 HU HU9603627A patent/HUT77720A/hu unknown
- 1995-06-30 IL IL11441595A patent/IL114415A0/xx unknown
- 1995-06-30 ZA ZA955471A patent/ZA955471B/xx unknown
- 1995-06-30 MY MYPI95001822A patent/MY130597A/en unknown
-
1996
- 1996-12-23 NO NO965556A patent/NO965556L/no unknown
- 1996-12-27 KR KR1019960707474A patent/KR100218495B1/ko not_active IP Right Cessation
- 1996-12-31 FI FI965292A patent/FI965292A0/fi not_active Application Discontinuation
- 1996-12-31 OA OA60946A patent/OA10341A/en unknown
-
1997
- 1997-01-27 BG BG101175A patent/BG101175A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA955471B (en) | 1996-12-30 |
| BG101175A (en) | 1997-08-29 |
| KR100218495B1 (en) | 1999-09-01 |
| EP0768881A2 (en) | 1997-04-23 |
| TW401303B (en) | 2000-08-11 |
| AU693911B2 (en) | 1998-07-09 |
| HUT77720A (hu) | 1998-07-28 |
| FI965292A (fi) | 1996-12-31 |
| MY130597A (en) | 2007-07-31 |
| EP0768881B1 (en) | 2002-06-12 |
| JP2945481B2 (ja) | 1999-09-06 |
| JPH09507858A (ja) | 1997-08-12 |
| EE9600180A (et) | 1997-06-16 |
| IL114415A0 (en) | 1995-10-31 |
| ATE218867T1 (de) | 2002-06-15 |
| AP9600896A0 (en) | 1997-01-31 |
| CN1091599C (zh) | 2002-10-02 |
| NO965556D0 (no) | 1996-12-23 |
| OA10341A (en) | 1997-10-07 |
| CN1151697A (zh) | 1997-06-11 |
| AU2924895A (en) | 1996-01-25 |
| DE69527066D1 (de) | 2002-07-18 |
| WO1996001110A3 (en) | 1996-02-22 |
| CA2193489A1 (en) | 1996-01-18 |
| WO1996001110A2 (en) | 1996-01-18 |
| MX9700044A (es) | 1997-04-30 |
| CZ375596A3 (en) | 1997-04-16 |
| PL317891A1 (en) | 1997-04-28 |
| HU9603627D0 (en) | 1997-02-28 |
| BR9508201A (pt) | 1997-11-11 |
| FI965292A0 (fi) | 1996-12-31 |
| DE69527066T2 (de) | 2003-02-13 |
| NO965556L (no) | 1996-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0876387B1 (en) | Use of roxithromycin for the preparation of a medicament for improving the biological and antiviral activity of protease inhibitors | |
| US20060229293A1 (en) | Compositions for the treatment of hepatitis C and methods for using compositions for the treatment of hepatitis C | |
| EP0286224A2 (en) | Treatment of human viral infection by dsRNA combined with viral inhibitors | |
| EP2083825A1 (en) | Compositions for the treatment of hepatitis c and methods for using compositions for the treatment of hepatitis c | |
| CA2063417C (en) | Antiviral composition | |
| Nelson et al. | Emtricitabine (FTC) for the treatment of HIV infection | |
| AU2021261965A1 (en) | Regimens for treating hiv infections and aids | |
| SK168196A3 (en) | Anti-hiv triple combination | |
| DE68914990T2 (de) | Verfahren zur inhibierung der wirkung des menschlichen immunschwäche-virus (hiv) in vivo. | |
| WO1997037661A1 (fr) | Medicament de prevention et de traitement des infections virales | |
| US5541212A (en) | Use of cimetidine for the control of retrovirus infections | |
| Acosta et al. | Agents for treating human immunodeficiency virus infection | |
| Humphrey et al. | A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection | |
| Merry et al. | Ritonavir pharmacokinetics alone and in combination with saquinavir in HIV-infected patients | |
| AU716760B2 (en) | Aids therapeutic composition | |
| RU2331420C2 (ru) | Противовирусное средство (варианты) и способ лечения на его основе | |
| Kahn | The clinical use of didanosine | |
| EP1644040B1 (de) | Verwendung von kombinationen aus hemmern der reversen transkriptase und hemmern der viruscodierten dna-polymerase | |
| Fletcher | Current perspectives on antiretroviral therapy | |
| Galasso | Antiviral agents: a new beginning | |
| DE3821676A1 (de) | Verwendung von avaron oder avaron-derivaten in kombination mit 3'-azido-3'-deoxythymidin zur antiviralen therapie | |
| NZ335639A (en) | (R)-N-(1,1-dimethylethyl)-3-[(2S,3S)-2-hydroxy-3-[(R)-2-(5-isoquinolyloxyacetyl)amino-3-methylthiopropanoyl] amino-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxyamide (KNI-272) an another agent for the treatment of AIDS | |
| AU1133899A (en) | Mixtures of dideoxy-nucleosides and hydroxycarbamide for inhibiting retroviral spread | |
| WO1998042349A1 (en) | Mixtures of at least two reverse transcriptase inhibitors and hydroxycarbamide, in particular for inhibiting retroviral spread |